Arthritis

Updated 26 November 2015

Krystexxa Approved for Gout

For adults who can't use other therapies

0

This article has not necessarily been edited by Health24.

WEDNESDAY, Sept. 15 (HealthDay News) -- Krystexxa (pegloticase) has been approved by the U.S. Food and Drug Administration for adults with gout who do not respond to, or who cannot tolerate, standard treatments.

Gout results when the body produces too much uric acid, which crystallizes in the joints or soft tissue. This leads to symptoms including pain, stiffness, swelling and redness.

The condition has been strongly associated with other health issues including obesity, high blood pressure, high cholesterol and diabetes, the FDA said in a news release.

Krystexxa, given by injection every two weeks, metabolizes uric acid into a harmless byproduct that is excreted in the user's urine, the agency said. The drug's safety and effectiveness were established in a pair of six-month clinical trials involving a total of 212 people.

The FDA warned that since severe allergic reactions were a common side effect of Krystexxa, a corticosteroid and antihistamine should be given beforehand to minimize this risk. Other common adverse reactions have included gout flares, nausea, bruising at the injection site, nasal irritation, constipation, chest pain and vomiting.

The agency said Krystexxa hadn't been evaluated in people with congestive heart failure, and should be dispensed to such users with caution.

The drug is produced by Savient Pharmaceuticals, based in East Brunswick, N.J.

More information

To learn more about gout, visit U.S. National Library of Medicine.

Read more:

Causes of Gout

Treatment of Gout


(Copyright © 2010 HealthDay. All rights reserved.)

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Arthritis expert

Professor Asgar Ali Kalla completed his MBChB (Bachelor of Medicine and Bachelor of Surgery) degree in 1975 at the University of Cape Town and his FRCP in 2003 in London. Professor Ali Kalla is the Isaac Albow Chair of Rheumatology at the University of Cape Town and also the Head of Division of Rheumatology at Groote Schuur Hospital. He has participated in a number of clinical trials for rheumatology and is active in community outreach. Prof Ali Kalla is an expert in Arthritis for Health24.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules